Business
Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized
About this update from Black Diamond Therapeutics, Inc.
Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM CAMBRIDGE, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today announced multiple presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 – June 2, 2026, in Chicago. Details for the Oral Presentation: Session Type/Title: Rapid Oral Abstract Session - Lung Cancer—Non-Small Cell MetastaticTitle: Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in treatment-naïve patients with non-small cell lung cancer with non-classical EGFR mutationsAbstract: 8519Presenter: Julia Rotow, MD, Dana-Farber Cancer InstituteDate and Time: May 30, 2026, 1:15 PM-2:45 PM CDT (slides will be available at 8:00 AM EDT on the Black Diamond website here) Details for the Poster Presentations: Session Type/Title: Poster Session - Lung Cancer—Non-Small Cell MetastaticTitle: Safety and efficacy results of the phase 2 study of silevertinib (BDTX-1535) in previously treated patients with non-small cell lung cancer with non-classical and C797S EGFR mutationsAbstract: 8620Poster Board: 410Presenter: Helena Yu, MD, Memorial Sloan Kettering Cancer CenterDate and Time: May 31, 2026, 9:00 AM-12:00 PM CDT Session Type/Title: Poster Session - Central Nervous System TumorsTitle: Randomized phase 2 study to evaluate the efficacy and safety of silevertinib in combination with temozolomide in newly diagnosed patients with EGFRvIII-positive IDHwt MGMT unmethylated glioblastomaAbstract: TPS2098Poster Board: 460aPresenter: Patrick Wen, MD, Dana-Farber Cancer InstituteDate and Time: June 1, 2026, 1:30 PM-4:30 PM CDT Posters will become available on June 1, 2026 at 8:00 AM EDT on the Black Diamond Therapeutics website here. About Silevertinib Silevertinib is an oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that selectively targets classical and more than 50 non-classical EGFR mutations in NSCLC. It also potently inhibits key EGFR alterations seen in GBM, including EGFRvIII, while avoiding th...
View stock analysis, news, and events for Black Diamond Therapeutics, Inc.